United States securities and exchange commission logo





                             July 12, 2023

       Paul Berns
       Chief Executive Officer
       Neumora Therapeutics, Inc.
       65 Grove Street
       Watertown, Massachusetts 02472

                                                        Re: Neumora
Therapeutics, Inc.
                                                            Amendment No. 8 to
Draft Registration Statement on Form S-1
                                                            Submitted June 30,
2023
                                                            CIK No. 0001885522

       Dear Paul Berns:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 8 to Draft Registration Statement on Form S-1 submitted on
June 30, 2023

       Prospectus Summary
       Our Pipeline, page 2

   1.                                                   We note your new
disclosure here and elsewhere stating you expect to "rapidly progress
                                                        the development of
[y]our pipeline." Please revise this statement in each place that it
                                                        appears to remove the
implication that you may progress through the clinical trial process
                                                        at a faster rate, as
this is unknown and not entirely within your control.
   2.                                                   We note your response
to our prior comment 5; however, we reissue the comment. Please
                                                        revise to remove the
individual study progress rows and revert to a single row depicting
                                                        the overall current
phase of development for the indication. You may include additional
 Paul Berns
Neumora Therapeutics, Inc.
July 12, 2023
Page 2
      narrative disclosure around the pipeline table with detail of the
referenced studies for
      further context. In addition, please revise the prospectus to include
information regarding
      foreign jurisdictions where regulatory approvals will be sought, as noted
in your response
      letter, including a discussion of the regulatory regime of each, where
appropriate. Your
      disclosure should note whether you have initiated the approval process in
such
      jurisdictions or otherwise advise.
Business
NMRA-140 (KOR), page 124

3.    We note your response to our prior comment 2; however, we also note you
continue to
      refer to your results as "clinically meaningful" on page 126. Please
revise.
       You may contact Eric Atallah at 202-551-3663 or Al Pavot at 202-551-3738
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Daniel Crawford at 202-551-7767 or Laura Crotty at 202-551-7614 with any other
questions.



                                                            Sincerely,
FirstName LastNamePaul Berns
                                                            Division of
Corporation Finance
Comapany NameNeumora Therapeutics, Inc.
                                                            Office of Life
Sciences
July 12, 2023 Page 2
cc:       Phillip Stoup, Esq.
FirstName LastName